Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 7/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697126 | 0.89 | MAPT (0.64) | NOS1MAPTKDM4ECYP3A4PRMT6 | |
| Hydrochloric Acid SCHEMBL3273205 | 0.86 | MAPT (0.68) | NOS1MAPTKDM4ECYP3A4PRMT6 | |
| SCHEMBL14409172 | 0.81 | PRMT6 (0.63) | NOS1MAPTKDM4ECYP3A4PRMT6 | |
| SCHEMBL123838 | 0.81 | TSHR (0.61) | NOS1ENPP2PRSS1PRSS2PRSS3 | |
| SCHEMBL8441355 | 0.80 | KDM4E (0.54) | NOS1MAPTKDM4ECYP3A4PRMT6 | |
| SCHEMBL14326991 | 0.79 | TAAR1 (0.61) | MAPTKDM4EALDH1A1LMNATSHR | |
| SCHEMBL9999688 | 0.79 | ENPP2 (0.54) | NOS1ENPP2PRSS1PRSS2PRSS3 | |
| SCHEMBL24292849 | 0.78 | MAPT (0.52) | NOS1MAPTKDM4ECYP3A4PRMT6 | |
| SCHEMBL8617312 | 0.78 | MAPT (0.64) | NOS1MAPTKDM4ECYP3A4PRMT6 | |
| SCHEMBL20987907 | 0.78 | MAPT (0.52) | NOS1MAPTKDM4ECYP3A4PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190153620-A1 | LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2019-05-23 | — | — | US | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7250413-B2 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-31 | — | — | US | disclosed |
| EP-0997474-B1 | Antithrombotic agents | PFIZER (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6417203-B1 | HETEROCYCLIC AMIDES | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-6180627-B1 | INDOLE, INDAZOLE, BENZOTRIAZOLE AND BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0997474-A1 | Antithrombotic agents | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5021429-A | Histamine h2-antagonists; antisecretory-antiallergen agent; skin disorders and peptic ulcers | ALLEN & HANSBURYS LIMITED (GB) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190153620-A1 | LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | VDR, TRPM8, TRPM7 | NOS1 4325/4885MAPT 4579/4885KDM4E 4436/4885 |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | NOS1 4122/4885MAPT 1202/4885KDM4E 4569/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | NOS1 824/4885MAPT 158/4885KDM4E 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.